The Role of Tumor Suppressor DLC-1: Far From Clear

作者：Liu, Xu; Pan, Yao-Jie; Zheng, Jun-Nian^*; Pei, Dong-Sheng^*

来源：Anti-Cancer Agents in Medicinal Chemistry, 2017, 17(7): 896-901.

DOI：10.2174/1871520616666160907142754

• DLC-1
• tumor suppressor
• RhoGAP activity
• biomarker
• GTPase
• therapeutic target

Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC). @@@ Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. @@@ Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1. @@@ Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.

• 出版日期2017
• 单位徐州医科大学